October 11, 2019 / 11:52 PM / 6 days ago

IN BRIEF: Fed Circuit backs PTAB's nixing of Duke patent on rare disease treatment

A federal appeals court on Friday affirmed a decision that invalidated a Duke University pharmaceutical patent claim challenged by biotechnology company BioMarin Pharmaceutical Inc.

The U.S. Court of Appeals for the Federal Circuit affirmed a ruling by the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board that a claim in the Duke patent covering a method of treating the rare genetic disorder Pompe Disease should be canceled.

To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2ozieyH

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below